abstract |
This specification describes a method for selecting a cancer patient for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, a method of examining non-cancer cell-type bone marrow-derived suppressor cells, such as CD14-positive and HLA-DR- (lo / negative) cells, as a therapeutic index in the therapy with entinostat combination therapy is provided. . The second therapeutic agent can be an anti-PD-1 antibody such as nivolumab and pembrolizumab; an anti-PD-L1 antibody such as MPDL3280A; and exemestane. |